Vicuron Pharmaceuticals Inc.'s stock value skyrocketed on news that the firm has become the latest takeover target for Pfizer Inc., which made public its plan to buy the company for $29.10 per share, or about $1.9 billion - a 74-whopping-percent premium over the firm's 90-day average closing price and 21 percent higher than the highest historical closing price. (BioWorld Today)